glp 1 for mcas glp1 #glp1medications #mastcellactivation #mcas #chronicfatigue #neuroinflammation #bloodsugarbalance #diabetesresearch #metabolichealth #weightlossjourney #hearthealth #chronicillnesssupport… Mast Cell Activation Syndrome (MCAS)

Marlo G

However, combining retatrutide with other GLP-1 agonists like semaglutide or tirzepatide is redundant and potentially dangerous, as you would be stacking activation of the same receptor pathways

Clinical trials demonstrate HbA1c reductions of 0.8-1.0% from baseline, with greater reductions observed in patients with higher baseline HbA1c levels

The timing of fatigue onset relative to medication initiation provides important diagnostic information, though coincidental conditions may emerge during treatment

Weight loss varies depending on the dose and type of medication, with differences observed in head-to-head studies [117]

Fundamental Body Composition Principles Provide Context for Fat-Free and Skeletal Muscle Loss With GLP-1 RA Treatments, Journal of the Endocrine Society, Volume 8, Issue 11, November 2024, bvae164, 7